NCT06556849

Brief Summary

Purpose: To evaluate the effectiveness of Defocus Incorporated Multiple Segments (DIMS) in slowing myopia progression as a function of age in pediatric patients. Methods: This was a non-randomized experimenter-masked retrospective controlled observational study of European individuals aged 6 -16 years with progressive myopia but no ocular pathology. The charts of the participants allocated to receive DIMS spectacles (Hoya® MiyoSmart®) or single vision spectacle lenses (control group) were retrospectively reviewed. The key outcome variables, cycloplegic spherical equivalent (SE) and axial length (AL), were measured at baseline and at 36 month follow up. The results were stratified by age into four groups: patients that wore DIMS spectacles oldest or youngest than 10 years (respectively, group A, 20 patients mean age 13.6±2.2 and group C, 20 patients mean age 9.0±1.2) and age matched control groups (group B, 18 patients mean age 13.2±2.5 and group D, mean age 8.5±0.9).

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
80

participants targeted

Target at P50-P75 for all trials

Timeline
Completed

Started Dec 2020

Typical duration for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

December 1, 2020

Completed
Same day until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2020

Completed
3.6 years until next milestone

Study Completion

Last participant's last visit for all outcomes

June 30, 2024

Completed
19 days until next milestone

First Submitted

Initial submission to the registry

July 19, 2024

Completed
28 days until next milestone

First Posted

Study publicly available on registry

August 16, 2024

Completed
Last Updated

August 20, 2024

Status Verified

August 1, 2024

Enrollment Period

Same day

First QC Date

July 19, 2024

Last Update Submit

August 19, 2024

Conditions

Outcome Measures

Primary Outcomes (1)

  • SE

    spherical equivalent

    36 months

Secondary Outcomes (1)

  • AL

    36 months

Study Arms (4)

Group A: patients oldest than 10 years that wear DIMS lens

myopic patients oldest than 10 years of age that wore Defocus Incorporated Multiple Segments (DIMS) spectacles

Device: Defocus Incorporated Multiple Segments (DIMS)

Group B: patients oldest than 10 years that wear (control group)

myopic patients oldest than 10 years of age that wore single vision spectacle lenses (control group)

Device: Defocus Incorporated Multiple Segments (DIMS)

Group C: patients youngest than 10 years that wear DIMS lens

myopic patients youngest than 10 years of age that wore Defocus Incorporated Multiple Segments (DIMS) spectacles

Device: Defocus Incorporated Multiple Segments (DIMS)

Group D: patients youngest than 10 years (control group)

myopic patients youngest than 10 years of age that wore single vision spectacle lenses (control group)

Device: Defocus Incorporated Multiple Segments (DIMS)

Interventions

To evaluate the effectiveness of Defocus Incorporated Multiple Segments (DIMS) in slowing myopia progression as a function of age in pediatric patients.

Group A: patients oldest than 10 years that wear DIMS lensGroup B: patients oldest than 10 years that wear (control group)Group C: patients youngest than 10 years that wear DIMS lensGroup D: patients youngest than 10 years (control group)

Eligibility Criteria

Age6 Years - 16 Years
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17)
Sampling MethodNon-Probability Sample
Study Population

pediatric patients with documented progressive myopiua

You may qualify if:

  • patient age between 6-16 years
  • progressive myopia with cycloplegic spherical equivalent (SE) from -0.50 to -4.00 diopters (D)
  • astigmatism less than 2.50D, anisometropia under 1.25D

You may not qualify if:

  • genetic syndromes suspected (e.g., Stickler, Marfan, etc.)
  • systemic diseases
  • eye diseases (such as glaucoma, juvenile cataracts, retinal abnormalities, any form of strabismus)

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Luca Buzzonetti

Rome, Italy

Location

MeSH Terms

Conditions

Myopia

Condition Hierarchy (Ancestors)

Refractive ErrorsEye Diseases

Study Officials

  • Luca Buzzonetti

    Bambino Gesù IRCCS Children's Hospital

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
CASE CONTROL
Time Perspective
RETROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR INVESTIGATOR
PI Title
Head of Ophthalmology Unit

Study Record Dates

First Submitted

July 19, 2024

First Posted

August 16, 2024

Study Start

December 1, 2020

Primary Completion

December 1, 2020

Study Completion

June 30, 2024

Last Updated

August 20, 2024

Record last verified: 2024-08

Locations